%0 Journal Article %T IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma %+ Centre de Recherche Saint-Antoine (CRSA) %+ Service d'Anatomie et cytologie pathologiques [CHU Saint-Antoine] %+ Nutrition, Métabolismes et Cancer (NuMeCan) %+ Centre de Recherche Saint-Antoine (UMRS893) %A Vaquero, Javier %A Lobe, Cindy %A Tahraoui, Sylvana %A Clapéron, Audrey %A Mergey, Martine %A Merabtene, Fatiha %A Wendum, Dominique %A Coulouarn, Cédric %A Housset, Chantal %A Desbois-Mouthon, Christèle %A Praz, Françoise %A Fouassier, Laura %Z 2011 25574 and 2014 47502, Fondation de France %Z RS14/75-112), GEFLUC (2013), and ANR (ANR-17-CE14-0013-01, Ligue Contre le Cancer %< avec comité de lecture %@ 1078-0432 %J Clinical Cancer Research %I American Association for Cancer Research %V 24 %N 17 %P 4282-4296 %8 2018-09-01 %D 2018 %R 10.1158/1078-0432.CCR-17-3725 %M 29716918 %K growth-factor receptor %K biliary-tract cancer %K epithelial-mesenchymal transition %K human hepatocellular-carcinoma %K phase-2 trial %K open-label %K insulin %K oxaliplatin %K gemcitabine %K cetuximab %Z Life Sciences [q-bio]Journal articles %X Cholangiocarcinoma (CCA) is a desmoplastic tumor of the biliary tree in which epidermal growth factor receptor (EGFR) is overexpressed and contributes to cancer progression. Although, EGFR has been envisaged as a target for therapy, treatment with tyrosine kinase inhibitors (TKI) such as erlotinib did not provide therapeutic benefit in patients with CCA, emphasizing the need to investigate resistance mechanisms against EGFR inhibition. %G English %L hal-01808092 %U https://univ-rennes.hal.science/hal-01808092 %~ UNIV-RENNES1 %~ INRA %~ APHP %~ U938 %~ STATS-UR1 %~ NUMECAN %~ NUMECAN-TGTC %~ UR1-UFR-SVE %~ UR1-HAL %~ UR1-SDV %~ AGREENIUM %~ TEST-UR-CSS %~ UNIV-RENNES %~ SORBONNE-UNIVERSITE %~ SORBONNE-UNIV %~ SU-MEDECINE %~ SU-MED %~ SU-TI %~ ANR %~ UR1-BIO-SA %~ ALLIANCE-SU %~ TEST3-HALCNRS